Serono SA had a double dose of news Wednesday, stopping two of its Phase III programs: onercept for psoriasis, and newly partnered product Canvaxin for Stage IV melanoma. (BioWorld Today)
In what has proved to be a slow and somewhat bumpy road for gene therapy research, one company - Avigen Inc. - is gracefully bowing out in order to focus on more traditional drug development. (BioWorld Today)
Establishing a second major collaboration, this time in the fields of cancer and tissue repair, Curis Inc. and Genentech Inc. joined forces to discover and develop small-molecule modulators of an undisclosed pathway. (BioWorld Today)
Less than a year after withdrawing a proposed initial public offering, TolerRx Inc. dipped into the private markets, raising $31 million in a Series D round. (BioWorld Today)
